

# Antibiotic Susceptibility of *Acinetobacter baumannii* ATCC® BAA-3275™

| Antimicrobial          | MIC <sup>a</sup> | Interpretation <sup>b</sup> | Antimicrobial                   | MIC  | Interpretation |
|------------------------|------------------|-----------------------------|---------------------------------|------|----------------|
| Ampicillin / Sulbactam | 8                | S                           | Imipenem                        | 8    | I              |
| Cefazolin              | ≥64              | R                           | Levofloxacin                    | 1    | S              |
| Cefepime               | 32               | R                           | Meropenem                       | ≥16  | R              |
| Cefotaxime             | ≥64              | R                           | Piperacillin / Tazobactam       | ≥128 | R              |
| Ceftazidime            | ≥64              | R                           | Tetracycline                    | ≥16  | R              |
| Ceftriaxone            | ≥64              | R                           | Tobramycin                      | ≤1   | S              |
| Ciprofloxacin          | 2                | I                           | Trimethoprim / Sulfamethoxazole | ≥320 | R              |
| Gentamicin             | ≤1               | S                           |                                 |      |                |

<sup>a</sup> Antibiotic susceptibility was obtained using a Vitek2 AST-GN69 and AST-XN09 cards.

<sup>b</sup> Parameter set: MIC Interpretation Guideline: CLSI M100-S27 (2017)

Therapeutic Interpretation Guideline: Natural Resistance